® (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5% Prescribing Information. February, 2014. Data on File, Valeant Pharmaceuticals.
Thiboutot D, Zaenglein A, Weiss J, Webster G, Calvarese B, Chen D. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients.
J Am Acad Dermatol. 2008;59:792-800. Fu LW and Vender RB. Newer approaches in topical combination therapy for acne.
Skin Therapy Letter. 2011;16(9):1-8. American Academy of Dermatology. Who gets acne and causes. Available at: http://www.aad.org/dermatology-a-to-z/diseases-and-treatments/a---d/acne/who-gets-causes. Accessed Sept 5, 2014.
Russell JJ. Topical therapy for acne.
Am Fam Physician 2000;61(2):357-365. Cook-Bolden F. Clindamycin phosphate 1.2% and benzoyl peroxide 2.5%: a new, once-daily, fixed combination treatment for moderate to severe acne.
Cosmet Dermatol 20009;22(6):319-322. ACZONE
® (dapsone) Gel, 5% Prescribing Information. March, 2013. DUAC (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% Prescribing Information. December, 2013.
® (adalapene and benzoyl peroxide) Gel, 0.1%/2.5% Prescribing Information. January, 2013.
*This offer is only valid for patients with commercial insurance. Eligible uninsured patients will pay more. This offer is not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state, or other governmental programs, including, but not limited to, Medicare (including Medicare Advantage and Part A, B, and D plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan, or any other federal or state health care programs. This offer is good only in the U.S. at retail pharmacies owned and operated by Walgreen Co. (or its affiliates) or other participating independent retail pharmacies. This offer is not valid in Massachusetts or Minnesota or where otherwise prohibited, taxed or otherwise restricted.
Click here for other terms and conditions that apply.
Acanya (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5% is indicated for the topical treatment of acne vulgaris in patients 12 years of age or older.
IMPORTANT SAFETY INFORMATION
ACANYA Gel is contraindicated in patients with a known hypersensitivity to clindamycin, benzoyl peroxide, any component of the formulation, or lincomycin.
ACANYA Gel is contraindicated in patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.
Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin. ACANYA Gel should be discontinued if significant diarrhea occurs.
Orally and parenterally administered clindamycin has been associated with severe colitis, which may result in death.
Anaphylaxis, as well as other allergic reactions leading to hospitalizations, has been reported in postmarketing use of products containing clindamycin/benzoyl peroxide. If a patient develops symptoms of an allergic reaction such as swelling and shortness of breath, they should be instructed to discontinue use and contact a physician immediately.
The most common local adverse reactions experienced by patients in clinical trials were mild and moderate erythema, scaling, itching, burning and stinging.
ACANYA Gel should not be used in combination with erythromycin-containing products because of its clindamycin component.
Patients should be advised to avoid contact with the eyes or mucous membranes.
Patients should minimize exposure to natural and avoid artificial sunlight (tanning beds or UVA/B treatment) while using ACANYA Gel. To minimize exposure to sunlight, protective clothing should be worn and a sunscreen with SPF 15 rating or higher should be used.
®/™ are trademarks of Valeant Pharmaceuticals International, Inc. or its affiliates. Any other product or brand names and logos are the property of their respective owners.
© 2016 Valeant Pharmaceuticals North America LLC.